NASDAQ$MREO
Mereo Biopha-Adr · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
Mereo BioPharma reported second quarter 2026 financial results including zero revenue, a net loss of $7.0 million, and an expanded cash runway into late-2027 following a new licensing option agreement.
The company recorded no revenue and a net loss of $7.0 million for the quarter ended June 30, 2026, driven by reduced R&D and G&A expenses. Cash and cash equivalents stood at $30.1 million, now expected to fund operations into late-2027. Key developments included an option and license deal with Sentynl for alvelestat and ongoing regulatory discussions for setrusumab with Ultragenyx.
- Entered option and license agreement with Sentynl Therapeutics for alvelestat in AATD-LD, with potential $40 million upfront/R&D payments and up to $435 million milestones.
- Setrusumab Phase 3 studies missed primary fracture endpoints but showed significant BMD improvements and favorable safety; regulatory path discussions ongoing with FDA and MHRA.
- R&D expenses fell to $1.8 million and G&A to $5.2 million, contributing to a narrower net loss of $7.0 million versus $14.6 million in Q2 2025.
- Cash position of $30.1 million extended to fund operations into late-2027, excluding potential alvelestat option proceeds.
Headline financials
Revenue & EPS history
Mereo Biopha-Adr · Revenue · Quarterly
$0
Forward guidance
Cash runway extended into late-2027; Phase 3 alvelestat study targeted for early 2027 initiation if option exercised; setrusumab regulatory updates expected by year-end 2026.
Tailwinds
- Partnership with Sentynl provides non-dilutive funding potential and external development support for alvelestat.
- Extended cash runway reduces near-term financing needs.
- Regulatory engagement progressing for setrusumab path forward.
Headwinds
- Phase 3 setrusumab studies missed primary endpoints, requiring additional regulatory dialogue.
- No immediate revenue from product sales or partnerships recognized in the quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
+3.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+18.4%
Avg return
30 days after
69%
9 / 13 earnings
Positive
+11.9%
Q4 2023
Best reaction
-6.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +4.1% | +0.9% | +31.7% | |
| Q4 2025 | +4.6% | -4.5% | -4.3% | |
| Q3 2025 | +6.3% | +0.6% | +27.1% | |
| Q2 2025 | +9.4% | +14.5% | +19.7% | |
| Q1 2025 | +1.3% | -2.2% | +25.3% | |
| Q4 2024 | -3.6% | -11.6% | +15.6% | |
| Q3 2024 | -5.4% | -17.5% | -12.9% | |
| Q3 2023 | -5.4% | -17.5% | -12.9% | |
| Q2 2024 | +6.2% | +16.4% | +18.0% | |
| Q1 2024 | +10.5% | +10.1% | +43.6% | |
| Q1 2023 | +10.5% | +10.1% | +43.6% | |
| Q4 2023 | +11.9% | +15.6% | -7.1% | |
| Q4 2022 | -6.1% | -10.3% | +52.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro